Diseases related to cognitive impairment are one of the pending subjects of science, both due to the scarce knowledge that there is about what causes them, and because of the treatments or vaccines to prevent them. However, this week there has been good news related to one of the most recurrent among the population: Alzheimer’s.
Brigham and Women’s Hospital in Massachusetts has announced that your first clinical trial will begin very soon to get a nasal vaccine against this type of dementia. The vaccine may prevent or delay the onset of this syndrome.
According to the hospital statement, the trial will initially be limited, counting only 16 people between the ages of 60 and 85 with Alzheimer’s symptoms. These people will receive two doses of the vaccine one week apart.
Decades of research have suggested that boosting the immune system might somehow help eliminate beta-amyloid plaques in the brain. The accumulation of this peptide of 36 to 43 amino acids that is synthesized from the amyloid precursor protein is associated with the development of the disease.
The beta-amyloid plaques adhere to the brain alternating the person’s ability to think or remember information. For this reason, the nasal vaccine will spray a medicine called Protollin directly into the nasal passage; This medicine will activate immune cells to work to remove plaque.
According to recent dataUp to 5.8 million Americans are living with Alzheimer’s disease and it is one of the leading causes of death among American adults. Almost 122,000 people died in the country from this disease in 2019.